VEGF-C gene therapy - Herantis Pharma

Drug Profile

VEGF-C gene therapy - Herantis Pharma

Alternative Names: Ad-VEGF-C - Herantis Pharma; Lymfactin

Latest Information Update: 19 Jan 2016

Price : $50

At a glance

  • Originator Laurantis Pharma
  • Developer Herantis Pharma
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor C expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lymphoedema

Most Recent Events

  • 19 Jan 2016 Herantis Pharma plans a phase I trial for Lymphema in Europe (company pipeline; January 2016)
  • 13 Nov 2015 The Finnish Medicines Agency authorises Herantis Pharma's first-in-man clinical study for secondary Lymphoedema in Finland
  • 12 Oct 2015 Preclinical development is ongoing in Finland for Lymphoedema (secondary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top